{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:47:34Z","timestamp":1777502854585,"version":"3.51.4"},"reference-count":59,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2015,4,23]],"date-time":"2015-04-23T00:00:00Z","timestamp":1429747200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0123944","type":"journal-article","created":{"date-parts":[[2015,4,23]],"date-time":"2015-04-23T20:23:09Z","timestamp":1429820589000},"page":"e0123944","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":29,"title":["Identification of Broad-Genotype HPV L2 Neutralization Site for Pan-HPV Vaccine Development by a Cross-Neutralizing Antibody"],"prefix":"10.1371","volume":"10","author":[{"given":"Daning","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihai","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jieqiong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yajing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Xin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minxi","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhibo","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaowei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ningshao","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2015,4,23]]},"reference":[{"issue":"Suppl 5","key":"ref1","doi-asserted-by":"crossref","first-page":"F12","DOI":"10.1016\/j.vaccine.2012.07.055","article-title":"Global burden of human papillomavirus and related diseases","volume":"30","author":"D Forman","year":"2012","journal-title":"Vaccine"},{"issue":"Suppl 5","key":"ref2","doi-asserted-by":"crossref","first-page":"F71","DOI":"10.1016\/j.vaccine.2012.05.091","article-title":"Therapy of human papillomavirus-related disease","volume":"30","author":"PL Stern","year":"2012","journal-title":"Vaccine"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.virol.2013.04.023","article-title":"Cross-roads in the classification of papillomaviruses","volume":"445","author":"EM de Villiers","year":"2013","journal-title":"Virology"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.virol.2013.06.007","article-title":"Diseases associated with human papillomavirus infection","volume":"445","author":"HA Cubie","year":"2013","journal-title":"Virology"},{"issue":"Suppl 3","key":"ref5","first-page":"S3\/11","article-title":"Chapter 2: The burden of HPV-related cancers","volume":"24","author":"DM Parkin","year":"2006","journal-title":"Vaccine"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.ygyno.2008.02.003","article-title":"Immunobiology of HPV and HPV vaccines","volume":"109","author":"M Stanley","year":"2008","journal-title":"Gynecol Oncol"},{"key":"ref7","first-page":"1","article-title":"Human papillomavirus (HPV) prevalence and HPV type distribution in cervical, vulvar, and anal cancers in central and eastern Europe","volume":"22","author":"M Skamperle","year":"2013","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat"},{"key":"ref8","first-page":"50","article-title":"Papillomavirus-like particle vaccines","author":"JT Schiller","year":"2001","journal-title":"J Natl Cancer Inst Monogr"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jmb.2008.05.079","article-title":"A quantitative description of in vitro assembly of human papillomavirus 16 virus-like particles","volume":"381","author":"S Mukherjee","year":"2008","journal-title":"J Mol Biol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial","volume":"367","author":"DM Harper","year":"2006","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(05)70101-7","article-title":"Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial","volume":"6","author":"LL Villa","year":"2005","journal-title":"Lancet Oncol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/ijc.20244","article-title":"Against which human papillomavirus types shall we vaccinate and screen? The international perspective","volume":"111","author":"N Munoz","year":"2004","journal-title":"Int J Cancer"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.virol.2013.04.017","article-title":"L2, the minor capsid protein of papillomavirus","volume":"445","author":"JW Wang","year":"2013","journal-title":"Virology"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"10085","DOI":"10.1128\/JVI.01088-09","article-title":"Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines","volume":"83","author":"C Schellenbacher","year":"2009","journal-title":"J Virol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"e23310","DOI":"10.1371\/journal.pone.0023310","article-title":"A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2","volume":"6","author":"E Tumban","year":"2011","journal-title":"PLoS One"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1093\/jnci\/djp106","article-title":"Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines","volume":"101","author":"S Jagu","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1016\/j.vaccine.2010.04.039","article-title":"Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection","volume":"28","author":"S Jagu","year":"2010","journal-title":"Vaccine"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1073\/pnas.0508815103","article-title":"Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection","volume":"103","author":"RM Richards","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"11426","DOI":"10.1128\/JVI.01721-13","article-title":"Multiple heparan sulfate binding site engagements are required for the infectious entry of human papillomavirus type 16","volume":"87","author":"KF Richards","year":"2013","journal-title":"J Virol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"13927","DOI":"10.1128\/JVI.00936-07","article-title":"A protective and broadly cross-neutralizing epitope of human papillomavirus L2","volume":"81","author":"R Gambhira","year":"2007","journal-title":"J Virol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.virol.2010.10.017","article-title":"The N-terminal region of the human papillomavirus L2 protein contains overlapping binding sites for neutralizing, cross-neutralizing and non-neutralizing antibodies","volume":"409","author":"I Rubio","year":"2011","journal-title":"Virology"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"e49751","DOI":"10.1371\/journal.pone.0049751","article-title":"VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus","volume":"7","author":"E Tumban","year":"2012","journal-title":"PLoS One"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"e95448","DOI":"10.1371\/journal.pone.0095448","article-title":"A vaccine of L2 epitope repeats fused with a modified IgG1 Fc induced cross-neutralizing antibodies and protective immunity against divergent human papillomavirus types","volume":"9","author":"X Chen","year":"2014","journal-title":"PLoS One"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"e39741","DOI":"10.1371\/journal.pone.0039741","article-title":"Development of AAVLP(HPV16\/31L2) particles as broadly protective HPV vaccine candidate","volume":"7","author":"K Nieto","year":"2012","journal-title":"PLoS One"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1128\/IAI.67.8.4290-4294.1999","article-title":"Expression and immunogenicity of a mutant diphtheria toxin molecule, CRM(197), and its fragments in Salmonella typhi vaccine strain CVD 908-htrA","volume":"67","author":"N Orr","year":"1999","journal-title":"Infect Immun"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev.iy.12.040194.001355","article-title":"Assembly, transport, and function of MHC class II molecules","volume":"12","author":"P Cresswell","year":"1994","journal-title":"Annu Rev Immunol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.4049\/jimmunol.148.8.2446","article-title":"MHC interaction and T cell recognition of carbohydrates and glycopeptides","volume":"148","author":"GY Ishioka","year":"1992","journal-title":"J Immunol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0140-6736(04)16725-1","article-title":"Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction","volume":"364","author":"CL Trotter","year":"2004","journal-title":"Lancet"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jama.2007.29-c","article-title":"Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial","volume":"299","author":"MD Snape","year":"2008","journal-title":"JAMA"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"10710","DOI":"10.1016\/S0021-9258(19)70365-2","article-title":"ADP-ribosylation of elongation factor 2 by diphtheria toxin. NMR spectra and proposed structures of ribosyl-diphthamide and its hydrolysis products","volume":"255","author":"BG Van Ness","year":"1980","journal-title":"J Biol Chem"},{"key":"ref31","first-page":"1504","article-title":"Structure and activity of diphtheria toxin. II. Attack by trypsin at a specific site within the intact toxin molecule","volume":"246","author":"R Drazin","year":"1971","journal-title":"J Biol Chem"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"e4463","DOI":"10.1371\/journal.pone.0004463","article-title":"Two highly conserved cysteine residues in HPV16 L2 form an intramolecular disulfide bond and are critical for infectivity in human keratinocytes","volume":"4","author":"SK Campos","year":"2009","journal-title":"PLoS One"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1743-422X-6-81","article-title":"Antigenic presentation of heterologous epitopes engineered into the outer surface-exposed helix 4 loop region of human papillomavirus L1 capsomeres","volume":"6","author":"Y Murata","year":"2009","journal-title":"Virol J"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"13447","DOI":"10.1128\/JVI.78.24.13447-13454.2004","article-title":"The positively charged termini of L2 minor capsid protein required for bovine papillomavirus infection function separately in nuclear import and DNA binding","volume":"78","author":"A Fay","year":"2004","journal-title":"J Virol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"12546","DOI":"10.1074\/jbc.M208691200","article-title":"Interaction of L2 with beta-actin directs intracellular transport of papillomavirus and infection","volume":"278","author":"R Yang","year":"2003","journal-title":"J Biol Chem"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1128\/JVI.77.6.3531-3541.2003","article-title":"Cell surface-binding motifs of L2 that facilitate papillomavirus infection","volume":"77","author":"R Yang","year":"2003","journal-title":"J Virol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.virol.2006.08.037","article-title":"Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region","volume":"358","author":"K Kondo","year":"2007","journal-title":"Virology"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/330381a0","article-title":"Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein","volume":"330","author":"BE Clarke","year":"1987","journal-title":"Nature"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1006\/viro.2001.1146","article-title":"A novel human papillomavirus type 6 neutralizing domain comprising two discrete regions of the major capsid protein L1","volume":"289","author":"WL McClements","year":"2001","journal-title":"Virology"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1159\/000150415","article-title":"Hepatitis B virus core particles as epitope carriers","volume":"38","author":"P Pumpens","year":"1995","journal-title":"Intervirology"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"498","DOI":"10.7150\/thno.7457","article-title":"Protection against lethal enterovirus 71 challenge in mice by a recombinant vaccine candidate containing a broadly cross-neutralizing epitope within the VP2 EF loop","volume":"4","author":"L Xu","year":"2014","journal-title":"Theranostics"},{"key":"ref42","first-page":"578","article-title":"Construction and application of an Escherichia coli high effective expression vector with an enhancer","volume":"16","author":"WX Luo","year":"2000","journal-title":"Sheng Wu Gong Cheng Xue Bao"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1016\/j.vaccine.2004.11.064","article-title":"A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primates","volume":"23","author":"SW Li","year":"2005","journal-title":"Vaccine"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1074\/jbc.M410361200","article-title":"Mutational analysis of essential interactions involved in the assembly of hepatitis E virus capsid","volume":"280","author":"SW Li","year":"2005","journal-title":"J Biol Chem"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0022-1759(94)00307-I","article-title":"Preparation of monoclonal antibodies for the diagnosis of influenza A infection using different immunization protocols","volume":"180","author":"E Vareckova","year":"1995","journal-title":"J Immunol Methods"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1093\/nar\/gnh094","article-title":"A simple, rapid, high-fidelity and cost-effective PCR-based two-step DNA synthesis method for long gene sequences","volume":"32","author":"AS Xiong","year":"2004","journal-title":"Nucleic Acids Res"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1128\/JVI.78.2.751-757.2004","article-title":"Efficient intracellular assembly of papillomaviral vectors","volume":"78","author":"CB Buck","year":"2004","journal-title":"J Virol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.virol.2003.12.027","article-title":"Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18","volume":"321","author":"DV Pastrana","year":"2004","journal-title":"Virology"},{"key":"ref49","first-page":"445","article-title":"Generation of HPV pseudovirions using transfection and their use in neutralization assays","volume":"119","author":"CB Buck","year":"2005","journal-title":"Methods Mol Med"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.vaccine.2012.10.032","article-title":"Antigenic analysis of divergent genotypes human Enterovirus 71 viruses by a panel of neutralizing monoclonal antibodies: current genotyping of EV71 does not reflect their antigenicity","volume":"31","author":"Y Chen","year":"2013","journal-title":"Vaccine"},{"key":"ref51","article-title":"The PyMOL molecular graphics system","author":"WS Delano","year":"2002"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1007\/s00705-013-1713-8","article-title":"Development of human papillomavirus chimaeric L1\/L2 candidate vaccines","volume":"158","author":"M McGrath","year":"2013","journal-title":"Arch Virol"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.1016\/j.vaccine.2013.07.052","article-title":"A universal virus-like particle-based vaccine for human papillomavirus: longevity of protection and role of endogenous and exogenous adjuvants","volume":"31","author":"E Tumban","year":"2013","journal-title":"Vaccine"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.virol.2012.09.006","article-title":"Monoclonal antibodies recognizing cross-neutralization epitopes in human papillomavirus 16 minor capsid protein L2","volume":"434","author":"S Nakao","year":"2012","journal-title":"Virology"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"6188","DOI":"10.1128\/JVI.73.7.6188-6190.1999","article-title":"Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6","volume":"73","author":"K Kawana","year":"1999","journal-title":"J Virol"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/j.vaccine.2006.11.049","article-title":"A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11","volume":"25","author":"K Slupetzky","year":"2007","journal-title":"Vaccine"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1016\/j.vaccine.2014.04.032","article-title":"Low doses of flagellin-L2 multimer vaccines protect against challenge with diverse papillomavirus genotypes","volume":"32","author":"K Kalnin","year":"2014","journal-title":"Vaccine"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"6127","DOI":"10.1128\/JVI.03218-12","article-title":"Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine","volume":"87","author":"S Jagu","year":"2013","journal-title":"J Virol"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"e55538","DOI":"10.1371\/journal.pone.0055538","article-title":"Optimization of multimeric human papillomavirus L2 vaccines","volume":"8","author":"S Jagu","year":"2013","journal-title":"PLoS One"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0123944","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T18:59:30Z","timestamp":1691607570000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0123944"}},"subtitle":[],"editor":[{"given":"Lawrence","family":"Banks","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,4,23]]},"references-count":59,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2015,4,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0123944","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,23]]}}}